

ORIGINAL ARTICLE

Determination of median effective dose (ED₅₀) of scorpion antivenom against scorpion envenomation using a newly developed formula

Saganuwan Alhaji Saganuwan 

Department of Veterinary Physiology, Pharmacology and Biochemistry, College of Veterinary Medicine, University of Agriculture, Makurdi, Benue State, Nigeria

Correspondence

Saganuwan Alhaji Saganuwan, Department of Veterinary Physiology, Pharmacology and Biochemistry, College of Veterinary Medicine, University of Agriculture, Makurdi, Benue State, Nigeria.
Email: pharn_saga2006@yahoo.com

Abstract

Background: About 50 species of scorpions cause fatal scorpionism worldwide. Most of these are members of the Buthidae family, and include, among others, *Mesobuthus eupeus*, *Androctonus crassicauda*, *Leiurus abduhbayrami*, *Leiurus quinquestriatus*, *Tityus pachyurus* and *Androctonus australis*. Because high doses of scorpion venom and antivenom can cause death and hypersensitive reactions, there is a need to develop a formula that can be used to calculate both lethal and effective doses for scorpion venom and antivenom, respectively, thereby obviating the need for laboratory experiments.

Methods: In view of this, a literature search was carried out with the aim of modifying the formula ($LD_{50} = \frac{ED_{50}}{3} \times W_a \times 10^{-4}$) for calculation of the median lethal dose (LD₅₀) of scorpion venom and the ED₅₀ of antivenom. The human equivalent dose (HED) formula was assessed for extrapolation of LD₅₀ and ED₅₀ from animals to human for comparison and relevance with the new formula.

Results: The findings showed that the newly developed formula ($LD_{50} = ED_{50}^{1/3} \times W_a \times 10^{-4}$) yielded results that are very close to the reported values. Therefore, the newly developed and HED formulas can be used for calculation of LD₅₀ and ED₅₀ values for scorpion venom and antivenom, respectively.

Conclusion: The new formula yielded better results than the HED formula, confirming its predictive validity, precision, and reliability, thereby obviating the need for rigorous experiments and justifying the principles of reduction, refinement, and replacement (3Rs).

KEYWORDS

antivenom, ED₅₀, human equivalent dose, LD₅₀, Scorpion, venom

1 | INTRODUCTION

Scorpions are members of the order Scorpiones, class Arachnida, subgroup Arthropoda. Their poisonous stings (termed scorpionism) have caused innumerable deaths, and scorpionism has raised serious

concern worldwide because of its high incidence, prevalence, morbidity, and mortality.¹ About 2.3 billion people from Africa, the near and Middle-East and South India are at risk, and annual stings of over 1.2 million are reported, resulting in 3250 deaths, with higher severity and mortality among children.² However, mortalities have

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2018 The Authors. *Animal Models and Experimental Medicine* published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences

decreased in countries that use antivenoms.³ Scorpionism caused by *Tityus pachyurus* pollock is characterized by sialorrhoea, respiratory distress, profuse sweating, ataxia, restlessness, somnolence, and hypoglycemia in mice. However, the antivenoms Bioclon and Butantan, produced in Mexico and Brazil, respectively, are very effective against *T. pachyurus* Pocock.⁴ The toxicity of the venom is related to the maturity and weight of the scorpion.⁵

Out of 1500 species of scorpions, 46-50 species are lethal. The number of dangerous species in the Buthidae family is significantly higher than in other families. Despite the fact that scorpion envenomations are a considerable health problem in tropical and subtropical regions of the world, treatment requires the use of specific antiserum. In 1909, Charles Todd produced a serum that was effective against *Buthus quinquestriatus* venom by immunizing horses using crude venom as an antigen.^{6,7} The treatment requires a high amount of antivenom to yield satisfactory neutralization,⁸ which can lead to adverse reactions. Hence there is a need to assess the median effective dose (ED₅₀) of scorpion antivenom against the LD₅₀ of the venom, with a view to eliminating or reducing post-treatment adverse reactions and obviating the need for laboratory experiments.

2 | METHODS

A random search of the literature, including journals, textbooks, books of abstracts, conference proceedings, and other periodicals, was conducted to establish the species of poisonous scorpions, their venoms, antivenoms, median lethal doses (LD₅₀), median effective doses (ED₅₀), their immunogenic reactions and the formulas used for calculation of both LD₅₀ and ED₅₀.^{6,7,9-14} The following four formulas were extracted.

$$\text{Median Lethal Dose (LD}_{50}\text{)} = \text{ED}_{50}/3 \quad (1)$$

$$\text{LD}_{50} = \text{ED}_{50}/3 \times W_a \text{ (} W_a \text{ = Weight of animal incooperated)} \quad (2)$$

$$\text{LD}_{50} = \text{ED}_{50} \times W_a \times 10^{-4} \text{ (} 10^{-4} \text{ = Safety factor incooperated)} \quad (3)$$

$$\text{LD}_{50} = \text{ED}_{50} 1/3 \times W_a \times 10^{-4} \text{ (} 1/3 \text{ = Therapeutic exponent)} \quad (4)$$

Based on the above formulas, the initial formula ($\text{LD}_{50} = \frac{\text{ED}_{50}}{3} \times W_m \times 10^{-4}$) developed by Saganuwan¹⁵ is therefore modified to ($\text{LD}_{50} = \text{ED}_{50}^{1/3} \times W_m \times 10^{-4}$).

A one-third exponent was used to provide therapeutic scaling of dose translation from animal to animal.¹⁶ The new formula was used to estimate ED₅₀ and LD₅₀ values for venom from *Mesobuthus eupeus*, *Androctonus crassicauda*, *Leiurus abdullahbayrami*, *Hottentotta saulcyi*, *Leiurus quinquestriatus* and *T. pachyurus* and *Androctonus australis*. ED₅₀ and LD₅₀ values were also calculated using the human equivalent dose (HED) formulas, and the two sets of values were compared with the values reported in the literature. Animal-human and human-animal ED₅₀ and LD₅₀ values of *T. pachyurus* venom and antivenom were respectively calculated using the new and human HED formulas. HED is equal to the animal dose multiplied by the

animal correction factor (K_m) divided by the human K_m factor. The K_m factor is body weight (kg) divided by body surface area (m²). Body weights and body surface areas of animals and humans were taken from Reagan-Shaw et al¹⁶ and USEPA.¹⁷ The ED₅₀s for antivenom against *M. eupeus*, *A. crassicauda* and *T. pachyurus* have been established,^{4,6,9-11} but were recalculated using the new and HED formulas. The routes of administration are indicated in Table 1.

3 | RESULTS

Species of scorpions, experimental LD₅₀s of scorpion venoms, therapeutic ED₅₀ values of scorpion antivenoms and their calculated ED₅₀ values are presented in Table 1. *Androctonus australis* is the most poisonous among the seven species, followed by *T. pachyurus*, *A. crassicauda*, *L. quinquestriatus*, *M. eupeus*, *Leiurus abdullahbayrami* and *H. saulcyi*, in that order (Table 1). Species of animals, their body weights, BSAs, km factors, human equivalent doses, calculated LD₅₀s for *Tityus pachyurus* venom and ED₅₀ values of the antivenom are presented in Table 2.

4 | DISCUSSION

The new formula yielded higher estimated doses of scorpion antivenom. The severity of toxicity signs are directly related to LD₅₀. The lower the LD₅₀ value, the more severe the toxicity signs. Therefore, *A. australis* venom with an LD₅₀ (0.5 ng/kg) is the most dangerous among all the species of scorpions followed by *T. pachyurus* (4.8 µg/kg) and *A. crassicauda* (15.45 µg/kg) venom. Our findings are corroborated by a report that *Tityus stigmurus* envenomation caused death in humans characterized by cardiogenic shock, pulmonary edema, and severe neurological symptoms.²⁰ The effect of scorpion venom on the frequency, but not the amplitude, of spontaneous glycinergic and glutamatergic postsynaptic currents suggests that scorpion toxin acts on inhibitory and excitatory presynaptic nerves.²¹ Scorpion venom toxicity increases in a dose-dependent fashion. The decreasing order of acute toxicity of *A. australis*, *T. pachyurus*, *A. crassicauda*, *L. quinquestriatus*, *M. eupeus*, *L. abdullahbayrami* and *H. saulcyi* venoms shown in Table 1 agrees with a report indicating that members of Buthidae family are of medical importance.¹²

Androctonus crassicauda scorpion venom has active constituents that could induce a sustained activation of human monocytes, expressed as IL-12.²² The venom has a distinct molecular mass component, from which two peptides (Acra 1 and Acra 2) have been fully amino acid sequenced. The peptides are similar to known sodium channel-specific toxins of other scorpions.²³ Scorpion antivenom has preventive, neutralizing, and curative properties against *M. eupeus* scorpionism if applied at optimum time, dose and route.⁹ The LD₅₀ of *A. crassicauda* venom has been estimated as 1.1 mg/kg by electrical stimulation and 39.19 mg/kg by maceration of telson.¹⁰ This venom has the lowest elimination rate among all known scorpion venoms, making it highly toxic. The long half-life of the venom

TABLE 1 The species of scorpions, average weights of experimental animals, median lethal dose (LD₅₀) and effective dose 50 (ED₅₀) of scorpion venoms and antivenoms

S/no	Species of scorpion	Species of experimental animal	Average weight (g)	Reported LD ₅₀ of scorpion venom	Reported ED ₅₀ of antivenom	ED ₅₀ by the new formula	ED ₅₀ by HED formula	Reference(s)	Comments
1	<i>Mesobuthus eupeus</i>	Swiss albino mice Rabbit	20 ± 2.0 200 ± 2.0	0.18 mg/kg ^a i.m. 4.5 mg/kg	1 ml of <i>Androctonus crassicauda</i> neutralized 464 LD ₅₀ of <i>M. eupeus</i> in mice	4.5 mg/kg 2.82 mg/kg	0.35 mg/kg 1.0 mg/kg	6,9	ED ₅₀ is unknown
2	<i>Androctonus australis</i>	Mice	20.0 ± 1.0	0.5 mg/kg ^a , 12 mg/kg ^a , 0.25 mg/kg	16–18 µg	6.3 ng–5 mg/kg	0.48 ng–0.39 mg/kg	18	ED ₅₀ is unknown
3	<i>Androctonus crassicauda</i>	Swiss albino mice	25.0 ± 1.0	0.27 mg/kg, 15.45 µg/kg ^a i.c.v. 1.1 mg/kg, 39.19 mg/kg i.v. 35 µg/kg ^a s.c. 0.8–1.3 mg/kg	1 mL of <i>A. crassicauda</i> antivenom neutralized 940 LD ₅₀ of <i>A. crassicauda</i> venom in mice	5.1 mg/kg, 4.6 µg/kg, 8.2 mg/kg, 27.0 mg/kg i.v. 26.0 µg/kg s.c. 7.4–11.5 mg/kg ²	0.49 mg/kg, 0.44 µg/kg, 0.79 mg/kg, 2.61 mg/kg, 2.51 µg/kg, 0.74–1.11 mg/kg	6,7,10,11	ED ₅₀ is unknown
4	<i>Leiurus abdullahbayrami</i>	Mice	20.0 ± 2.0	0.19 mg/kg ^a s.c.	—	4.6 mg/kg	0.36 mg/kg	11	ED ₅₀ is unknown
5	<i>Hottentotta saulcyi</i>	Mice	20.0 ± 1.0	0.73 mg/kg s.c.	—	7.1 mg/kg	0.55 mg/kg	13	ED ₅₀ is unknown
6	<i>Leiurus quinquestriatus</i>	Rabbit	2000 ± 200	0.16–0.5 mg/kg ^a	—	0.93–1.4 mg/kg	0.33–0.50 mg/kg	19	ED ₅₀ is unknown
7	<i>Tityus pachyurus</i>	Swiss Webster mice	19.0 ± 1.0	4.8 µg/kg ^a	330 µg/mL (Biocon) 292 µg/mL (Butantan)	13.6 mg/kg	1.0 mg/kg	4	High chance of hypersensitivity reaction

—: No available information.

^aHighly toxic.

TABLE 2 Mouse-human and human-other animals extrapolated median lethal dose (LD₅₀) and effective dose 50 (ED₅₀) of *Tityus pachyurus* venom and antivenom

S/no	Species	Body weight (kg)	BSA (m ²)	K _m factor	HED calculated LD ₅₀ (μg/kg)	HED calculated ED ₅₀ (μg/kg)	ED ₅₀ by the new formula (μg/kg)
1	Mouse	0.02	0.007	2.9	4.8	13.6	133.3
2	Hamster	0.08	0.02	4.0	3.48	7.6	75.7
3	Rat	0.15	0.025	6.0	2.32	5.4	53.7
4	Guinea pig	0.4	0.064	5.8	2.40	3.9	39.1
5	Rabbit	1.8	0.15	12.0	1.16	1.9	18.6
6	Monkey	3.0	0.24	12.5	1.11	1.5	15.5
7	Cat	7.0	0.37	18.9	0.74	1.0	10.0
8	Dog	10.0	0.50	20.0	0.70	0.9	8.9
9	Baboon	12.0	0.60	20.0	0.70	0.8	8.4
10	Ferret	0.30	0.043	7.0	1.99	4.0	40.5
11	Marmoset	0.35	0.06	5.8	2.40	4.1	40.9
12	Squirrel monkey	0.6	0.09	6.7	2.08	3.3	32.6
13	Micro-pig	20.0	0.74	27.0	0.52	0.6	29.6
14	Mini-pig	40.0	1.14	35.1	0.40	0.5	21.5
15	Child	20.0	0.8	25.0	0.56	0.7	30.4
16	Adult human	60.0	1.6	37.5	0.37	0.4	4.0

BSA: body surface area; HED: human equivalent dose formula; K_m: metabolism constant (body weight [kg] divided by body surface area).

suggests the need for long-acting antivenom for venom neutralization.²⁴ Envenomation by *L. abdullahbayrami* causes hyperexcitability, agitation, aggressive behavior, squeaking, fighting, tachypnea, weakness, convulsion, and death due to cardiac and respiratory failure in mice.¹² Envenomation by *L. quinquestriatus* produced degranulation of eosinophils, fever, oedema of cerebrum and myocarditis in rabbit.¹⁴ The reports confirm the medical importance of members of the Buthidae family.

Bio-distribution of two purified toxic fractions of *M. eupeus* toxin in mice show rapid clearance of the compounds from blood and tissue, except for the kidneys,²⁵ signifying that *M. eupeus* toxicity may not last long in the body. Dissociation of the toxin-channel complex during depolarization is determined by the difference between electrical energies of the activated states of normal and toxin-modified channels.²⁶ Injection of partially purified toxic fractions into rabbits gave rise to more potent antivenoms than those presently available, generated using whole venom,²⁷ signifying that purification could reduce the dose of antivenoms needed. The antivenom for *A. crassicauda* venom, with an LD₅₀ (15.45 μg/kg) in mice,¹⁰ neutralized *Mesobuthus gibosus* venom (LD₅₀ 20 μg/kg) in the Aegean region of Turkey.⁶ Thus, highly potent antivenom could be produced from about 238 telsons in 51 days.²⁸

The calculated ED₅₀/LD₅₀ ratios for Butantan (292 μg/mL) and Bioclon (330 μg/mL) antivenoms and tityus toxin, the toxic principle of *Tityus* species, are $\frac{292}{13.6}$ and $\frac{330}{13.6}$, respectively, which give equivalent weights of 21.5 and 24.3 kg, showing that Butantan (292 μg/mL) and Bioclon (330 μg/mL) antivenoms could be used effectively in the treatment of humans weighing 21.5–24.3 kg, and signifying that age must be considered in the treatment of tityus toxin.²⁹ However, the difference in severity of symptoms observed in children and adults

may be due to differences in the pharmacokinetics of the toxin. *M. eupeus* venom can be neutralized by monovalent, polyvalent and anti-idiotypic antivenoms, which are non-toxicants and can be used as a vaccine in people at risk of scorpion stings.³⁰ Lack of a reported effective dose of antivenoms for *L. abdullahbayrami*, *L. quinquestriatus*, *H. saulcyi*, *M. eupeus* and *A. crassicauda* shows the need for specific antivenoms for a number of scorpion species.

Scorpion antivenoms are specific antigens, detoxified venoms, toxins, purified venom fractions, natural toxoids, recombinant toxins, synthetic peptides, and monoclonal and recombinant antibodies.⁷ Using peptides derived from the sequence of scorpion toxins, the penetration of antipeptide antibodies can neutralize the cognate venom.³¹ Turkish antivenom against *A. crassicauda* is effective against other species of scorpions. Minimum lethal dose and minimum effective dose were used to evaluate the effect of Turkish antivenom on *M. gibbosus* envenomation,¹⁸ suggesting the predictive validity, precision, and reliability of the new formula in envenomotherapy. Scorpion stings result in adult morbidity and pediatric mortality¹ and the most lethal species are *Tityus serrulatus* and *Tityus bahiensis* in Brazil, *Centruroides suffusus*, *Centruroides lionpidus*, and *Centruroides sculpturatus* in Mexico, *L. quinquestriatus*, *A. crassicauda*, *A. mauretanicus*, *A. australis*, *A. amoreuni*, and *Buthus occitanus* in the Middle East and North Africa, *Parabuthus grauntatus* and *Parabuthus transvaalicus* in South Africa, and *Mesobuthus tamulus* and *Palamneus swammerdame* in India^{32–35}.

Androctonus australis has complex venom that contains cytotoxic principles with very rapid resultant fatal effects.³⁶ Effective monoclonal antibodies (mAbs) specific to the α-neurotoxin 1 (Aah1) from *A. australis* hector venom have been reported,³⁷ which also has recombinant toxin II with immunological and biological properties.³⁸

In addition, *A. australis* hector envenomation is mediated by cytokines and the complement system, which activate in turn to damage tissue.³⁹ Kinins are also involved in cardiovascular toxicity and cause lethality of *L. quinquestriatus* venom in rabbits.⁴⁰ *A. australis garzonii* venom (100 µg/kg) was neutralized by 4 mg/kg of antivenom injected intravenously.⁴¹ Antivenoms against a number of scorpion venoms have been reported,⁴² but the potency of antivenom in relation to the potency of scorpion venom should be investigated⁴² and both LD₅₀ and ED₅₀ should be determined paradoxically and canonically.⁴³ The LD₅₀s of intravenous venom from *Vipera berus berus* (0.4 µg/kg; symptoms included head-drop, floppy neck, flaccid paralysis of limb, respiratory paralysis, and death),⁴⁴ *Laticauda colubrine* (0.05–0.13 µg/g),⁴⁵ Sri Lankan *Bungarus caeruleus* (0.07 µg/g),⁴⁶ *Naja sputatrix*⁴⁷ and *A. australis* (0.5 ng)¹⁸ show that the scorpion venoms are highly toxic. Similar symptoms were observed for *Vipera nikolskii* venom (1.0 µg/kg), but the symptoms, caused by phospholipase A₂, were lost after the mice were injected with strontium.¹⁸ Hence, strontium may be suitable as an antivenom against *V. berus berus* and *A. australis* venoms. The newly developed dot-ELISA for detection of the venoms of the Indian venomous snakes *Naja naja*, *B. caeruleus*, *Dabora russelli* and *Echis carinatus*⁴⁸ and proteomic enzyme analysis⁴⁹ may generally be used to detect scorpion venoms. The venoms of *Montivipera raddei* and *Montivipera bubjardahica*, which have high levels of toxicity, have been shown to have potent cytotoxicity against A549 human lung carcinoma,⁵⁰ signifying that scorpion venom may also have anticancer properties. Lethal doses of *L. quinquestriatus* were 0.5 mg/kg i.v. and 3 µg/kg i.m.³

The LD₅₀ of *T. pachyurus* venom and the ED₅₀ for its antivenom in monogastric animals are presented in Table 2. The results show that mouse (4.8 µg/kg) is the most sensitive to *T. pachyurus* venom followed by hamster (3.48 µg/kg), guinea pig (2.40 µg/kg), rat (2.32 µg/kg), rabbit (1.16 µg/kg), monkey (1.11 µg/kg), marmoset (2.40 µg/kg), squirrel monkey (2.08 µg/kg), ferret (1.99 µg/kg), cat (0.74 µg/kg), dog and baboon (0.70 µg/kg), child (0.56 µg/kg), micro-pig (0.52 µg/kg), mini-pig (0.40 µg/kg) and adult human (0.37 mg/kg) respectively, indicating that *T. pachyurus* venom is very toxic. The toxicity may be due to the presence of titytoxins that are also present in *T. pachyurus*, *T. stigmurus*, *Tityus abscurus* and *T. serrulatus* venom. The toxic principle acts via Na⁺, K⁺, Ca²⁺ and Cl⁻ channels, signifying excitation of heart, CNS, and muscular fibres.^{51–55} The reported ED₅₀s (0.4–13.6 µg/kg) for scorpion antivenoms for all the surveyed species using the HED formula are low, which may lead to therapeutic failure. The higher ED₅₀s (4.0–133.3 µg/kg) for all the species calculated using the new formula indicate an improved neutralization potential.⁴ Based on these calculations, the mini-pig could be the best model for determination of LD₅₀ and ED₅₀ for *T. pachyurus* venom and antivenom, respectively.

5 | CONCLUSION

This study showed that *A. australis* venom is the most toxic, followed by *T. pachyurus*, *A. crassicauda*, *L. quinquestriatus*, *M. eupeus*, *L.*

abdullabayrami, and *H. saulcyi*. The modified and HED formulas can be used to estimate the LD₅₀ and ED₅₀ values of the scorpion venoms and antivenoms, respectively. The newly developed formula, incorporating safety factor, animal weight and therapeutic index, yielded increased quantities of scorpion antivenoms, that should adequately neutralize the scorpion venoms, obviating the need for laboratory experiments and reducing the risk of hypersensitivity to the antivenoms.

CONFLICT OF INTEREST

None.

AUTHOR CONTRIBUTIONS

SA Saganuwan conceived the idea and wrote the manuscript.

ORCID

Saganuwan Alhaji Saganuwan  <http://orcid.org/0000-0002-0963-5569>

REFERENCES

- Santos MS, Silva CG, Neto BS, et al. Clinical and epidemiological aspect of scorpionism in the world: a systematic review. *Wilderness Environ Med.* 2016;27(4):504–518.
- Chippaux JP, Goyffon M. Epidemiology of scorpionism: a global appraisal. *Acta Trop.* 2008;107(2):71–79.
- Chippaux JP. Epidemiological investigation on envenomation: from theory to practice. *J Venom Anim Toxins Incl Trop Dis.* 2012;18(4):446–450.
- Barona J, Otero R, Núñez V. Toxicological and immunological aspects of scorpion venom (*Tityus parachyurus*) neutralizing capacity of antivenom produced in Latin America. *Bidondica.* 2004;24(1):42–49.
- Ozkan O, Adiguzel S, Kar S, Yakistiran S, Cesaretli KY, Karaer KZ. Determination of potency and paraspecific effects of *Androctonus crassicauda* (Oliver, 1807) antivenom against *Mesobuthus gibbosus* (Brulle, 1832) venom (Scorpiones: Buthidae). *J Venom Anim Toxins Incl Trop Dis.* 2007;13(2):500–508.
- Ozkan O, Carhan A. The neutralizing capacity of *Androctonus crassicauda* antivenom against *Mesobuthus eupeus* scorpion venom. *Toxicol.* 2008;52(2):375–379.
- Carno AO, Chatzaki M, Horta CC, et al. Alternative methodologies of scorpion antivenom production. *Toxicol.* 2015;97:64–74.
- Ismail M. The scorpion envenoming syndrome. *Toxicol.* 1995;33(7):825–858.
- Zayerzadeh E, Koohi MK, Mirakabadi AZ, et al. Amelioration of cardio-respiratory perturbations following *Mesobuthus eupeus* envenomation in anesthetized rabbits with commercial polyvalent F(ab')₂ antivenom. *Toxicol.* 2012;59(2):249–256.
- Ozkan O, Kar S, Güven E, Ergun G. Comparison of proteins, lethality and immunogenic compounds of *Androctonus crassicauda* (Oliver, 1807) (Scorpiones: Buthidae) venom obtained by different methods. *J Venom Anim Toxins Incl Trop Dis.* 2007;13(4):844–856.
- van Zoelen SA, Ozkan O, Inceoglu B. Antigenic cross-reactivity anti-biotoxin antibody against *Androctonus crassicauda* venom. *J Arthropod Borne Dis.* 2015;9(2):176–183.

12. Ozkan O, Yagmur EA, Ark M. A newly described scorpion species *Leiurus abduallahbayrami* (Scorpion: Buthidae), and the lethal potency and in vivo effects of its venom. *J Venom Anim Toxins Incl Trop Dis*. 2011;17(4):414-421.
13. Yağmur EA, Özkan Ö, Kavaer KZ. Determination of the median lethal dose and electrophoretic pattern of Hottentotta Saalaji (Scorpiones: Buthidae) scorpion venom. *J Arthropod Borne Dis*. 2015;9(2):238-245.
14. Affifi SH, Elkashef R, Seddek AS, Salem DA. Light and transmission electron microscopical changes associated with *Leirus quinquestriatus* venom in rabbits. *Macedonian Vet Rev*. 2010;39(1):51-57.
15. Saganuwan SA. The new algorithm for calculation of median lethal dose (LD₅₀) and effective dose fifty (ED₅₀) of *Micrarus fulvius* venom and anti-venom in mice. *Int J Vet Sci Med*. 2016;4(1):1-4.
16. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. *FASEB J*. 2008;22(3):659-661.
17. US Environmental Protection Agency. (USEPA). Guideline for carcinogen risk assessment. *Fed. Regist*. 1986;51(185):33992-34003.
18. Ozkan O, Adiguzel S, Ates C, Bozyigit I, Filazi A. Optimization of antiscorpion venom production. *J Venom Anim Toxins Incl Trop Dis*. 2006;12(3):390-399.
19. Gueron M, Ilia R, Sofer S. The cardiovascular after scorpion envenomation. A review. *J Toxicol Clin Toxicol*. 1992;30(2):245-258.
20. Albuguerque CM, Santana Neto Pde L, Amorim ML, Pires SC. Pediatric epidemiological aspects of scorpionism and report on fatal Cases from Ttyu stigmaru stings (Scorpions Buthidae in state of Pernambuco, Brazil). *Rev Soc Bras Med Toop*. 2013;46(4):484-489.
21. Akaike H, Shin MC, Kubo C, Akaike N. Effects of scorpion toxin on excitatory and inhibitory presynaptic terminals. *Toxicology*. 2009;264(3):198-204.
22. Saadi S, Assarehzadegan MA, Pipelzadeh MH, Hadaddezfuli R. Induction of IL-12 from human monocytes after stimulation with *Androctonus crassicauda* scorpion venom. *Toxicon*. 2015;106:117-121.
23. Caliskan F, García BI, Coronas FI, Batista CV, Zamudio FZ, Possani LD. Characterization of venom components from the scorpion *Androctonus crassicauda* of Turkey. *Toxicon*. 2006;48(1):12-22.
24. Ismail M, Abdelsalam M, Al-Ahaidisb MS. *Androctonus crassicauda* (Olivier), a dangerous and unduly neglected scorpion – I Pharmacological and clinical studies. *Toxicon*. 1994;32(12):1599-1618.
25. Shirmardi SP, Shamsaei M, Gandomkar M, Sarie E, Ghannadi M, Zare A. Comparison of two purified toxic fractions from *Mesobuthus eupeus* scorpion. *J Venom Anim Toxins Incl Trop Dis*. 2010;16(4):639-646.
26. Mozhaeva GN, Naumov AP. Kinetics of interaction of scorpion with sodium channels on the Ranvier node membrane. *Neurophysiology*. 1980;12(6):619-626.
27. Delari P, van Rietschoten J, Rochat H. Scorpion venoms and neurotoxins: an immunological study. *Toxicon*. 1981;19(3):393-407.
28. Ozkan O, Adiguzel S, Yakistiran S, Filazi A. Study of the relationship between *Androctonus crassicauda* (Olivier, 1807; Scorpiones, Buthidae), venom toxicity and telson size weight and storing condition. *J Venom Anim Toxins Incl Trop Dis*. 2006;12(2):297-309.
29. Nunan EA, Arya V, Hochhaus G, Cardoso VN, Moraes-Santos T. Age effects on the pharmacokinetics of Tityustoxin from *Tityus serralatus* scorpion venom in rats. *Braz J Med Biol Res*. 2004;37(3):385-390.
30. Khoobdel M, Zahraei-Salehi T, Nayeri-Fasaei, B, et al. Purification of the immunogenic fractions and determination of toxicity in *Mesobuthus eupeus* (Scorpionida: Buthidae) Venom. *J Arthropod Borne Dis*. 2013;7(2):139-146.
31. Alvarenga LM, Dining CR, Grainer C, Chávez-Olórtegui C. Induction of neutralizing antibodies against *Tityus serralatus* scorpion toxins by immunization with a mixture of defined synthetic epitopes. *Toxicon*. 2002;40(1):89-95.
32. Salama MW, Sharshar KM. Surveillance study on scorpion species in Egypt and comparison of their crude venom protein files. *J Basic Appl Zool*. 2013;66(2):76-86.
33. Balozet L. Scorpionism in the Old World. In: Bucherl W, Buckley EE, eds. *Veronoms Animals and Their Venoms*, 1st edn. New York: Academic Press; 1971:379-381.
34. Theakston RD, Warrell DA, Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. *Toxicon*. 2003;41(5):541-557.
35. Khoobdel M, Nayeri Fasaei B, Zahraei Salehi T, et al. The production of monovalent and anti-idiotypic antivenom against *Mesobuthus eupeus* (Scorpionida: Buthidae) venom in rabbits. *Toxicon*. 2013;15(76):44-49.
36. Nafie MS, Daim MMA, Ali IAI, Abdel-Rahman MA, Nabil ZI. Proteomic and biochemical characterization of the Egyptian scorpion "*Androctonus australis*" venom. Abstract of 6th International Conference on Natural Toxins, Ismailia, December, 2014:1-2.
37. Clot-Faybesse O, Juin M, Rochat H, Devaux C. Monoclonal antibodies against the *Androctonus australis* hector scorpion neurotoxin 1: characterization and use for venom neutralisation. *FEBS Lett*. 1999;458(3):313-318.
38. Bougis PE, Rochat H, Smith LA. Precursors of *Androctonus australis* scorpion neurotoxins. Structures of precursors, processing outcomes, and expression of a functional recombinant toxin II. *J Biol Chem*. 1989;264(32):19259-19265.
39. Adi-Bessalem S, Hammoudi-Triki D, Laraba-Djebari F. Pathophysiological effects of *Androctonus australis* hector scorpion venom: tissue damages and inflammatory response. *Exp Toxicol Pathol*. 2008;60(4-5):373-380.
40. Fatani AJ, Furman BL, Zeitlin IJ. The involvement of plasma kinins in the cardiovascular effects of *Leiurus quinquestriatus* scorpion venom in anaesthetized rabbits. *Toxicon*. 1998;36(3):523-536.
41. Krifi MN, Savin S, Debray M, Bon C, El Ayeb M, Choumet V. Pharmacokinetic studies of scorpion venom before and after antivenom immunotherapy. *Toxicon*. 2005;45(2):187-198.
42. Laustsen AH, Solà M, Jappe EC, Oscoz S, Lauridsen LP, Engmark M. Biotechnological trends in spider and scorpion antivenom development. *Toxins (Basel)*. 2016;8(8):1-33.
43. Saganuwan SA, Onyeyili PA. The paradox of human equivalent dose formula: a canonical case study of *Abrus precatorius* aqueous leaf extract in mongastric animals. *Mac Vet Rev*. 2016;39(1):23-32.
44. Malina T, Krecsák L, Westerström A, et al. Individual variability of venom from the European adder (*Vipera berus berus*) from one locality in Eastern Hungary. *Toxicon*. 2017;135:59-70.
45. Tan CH, Wong KY, Tan KY, Tan NH. Venom proteome of the yellow-lipped sea krait, *Laticauda colubrine* from Bali: insights into sub-venomic diversity venom antigenicity and cross-neutralization by antivenom. *J Proteomics*. 2017;166:48-58.
46. Amf O, Tan CH, Ariarane GC, Qurashi N, Tan NH. Venomics of *Bungarus caeruleus* (Indian Krait): comparable venom profiles, variable immune re-activities among specimens from Sri Lanka, India and Pakistan. *J Proteomics*. 2017;164:1-18.
47. Tan NH, Wong KY, Tan CH. Venomics of *Naja sputatrix*, the Javan-spitting cobra: a short neurotoxin-driven venom needing improved antivenom neutralization. *J Proteomics*. 2017;157:18-32.
48. Shaikh IK, Dixit PP, Pawade BS, Waykar IG. Development of dot-ELISA for the detection of venoms of major Indian venomous snakes. *Toxicon*. 2017;139:66-73.
49. Choudhury M, McCleary RJR, Keshwani M, Kini RM, Velmurugan D. Comparison of proteomic profiles of two of the Big four snakes of India, the Indian cobra (*Naja naja*) and the common krait (*Bungarus caeruleus*) and analyses of their toxins. *Toxicon*. 2017;135:33-42.
50. Nalbantsoy A, Hempel BF, Petras D, et al. Combined venom profiling and cytotoxicity screening of the Radde's mountain viper (*Montivipera raddei*) and Mount Bulgar viper (*Montivipera bulgardaghica*)

- with potent cytotoxicity against human A549 lung carcinoma cells. *Toxicon*. 2017;135:71-83.
51. Fatani AJ. Comparative study between peripherally and centrally acting sublethal and lethal doses of *Leiurus quinquestriatus* scorpion venom in rabbits: the usefulness of the sodium channel blocker lidocaine. *Saudi Pharm J*. 2000;18(3):137-151.
52. Batista CV, Román-González SA, Salas-Castillo SP, Zamudio FZ, Gómez-Lagunas F, Possani LD. Proteomic analysis of the venom from the scorpion *Tityus stigmurus*: biochemical and physiological comparison with other *Tityus* species. *Comp Biochem Physiol C Toxicol Pharmacol*. 2007;146(1-2):147-157.
53. Pimenta AM, Stöcklin R, Favreau P, Bougis PE, Martin-Eauclaire MF. Moving pieces in a proteomic puzzle: mass finger printing of toxic fractions from the venom of *Tityus seroulatus* (Scorpiones, Buthidae). *Rapid Commun Mass Spectrom*. 2001;15(17):1562-1572.
54. Guerrero-Varga JA, Mourao CBF, Quintero-Hernandez V, Possani LD, Schwartz EF. Identification and phylogenetic analysis of *Tityus pachyurus* and *Tityus obscurus* novel putative Na⁺ – channel scorpion toxins. *PLoS ONE*. 2012;7(2):e30478.
55. Barona J, Batista CV, Zamudio FZ, et al. Proteomic analysis of the venom and characterization of toxins specific for Na⁺ – and K⁺ – channels from the Colombian scorpion *Tityus pachyurus*. *Biochim Biophys Acta*. 2006;1764(1):76-84.

How to cite this article: Saganuwan SA. Determination of median effective dose (ED₅₀) of scorpion antivenom against scorpion envenomation using a newly developed formula. *Animal Model Exp Med*. 2018;1:228–234. <https://doi.org/10.1002/ame2.12031>